Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radical cure of Plasmodium vivax malaria with 8-aminoquinolines (primaquine or tafenoquine) is complicated by haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD heterozygous females, because of individual variation in the pattern of X-chromosome inactivation (Lyonisation) in erythroid cells, may have low G6PD activity in the majority of their erythrocytes, yet are usually reported as G6PD "normal" by current phenotypic screening tests. Their haemolytic risk when treated with 8-aminoquinolines has not been well characterized. METHODS AND FINDINGS: In a cohort study nested within a randomised clinical trial that compared different treatment regimens for P. vivax malaria, patients with a normal standard NADPH fluorescent spot test result (≳30%-40% of normal G6PD activity) were randomised to receive 3 d of chloroquine or dihydroartemisinin-piperaquine in combination with primaquine, either the standard high dose of 0.5 mg base/kg/day for 14 d or a higher dose of 1 mg base/kg/d for 7 d. Patterns of haemolysis were compared between G6PD wild-type and G6PD heterozygous female participants. Between 21 February 2012 and 04 July 2014, 241 female participants were enrolled, of whom 34 were heterozygous for the G6PD Mahidol variant. Haemolysis was substantially greater and a larger proportion of participants reached the threshold of clinically significant haemolysis (fractional haematocrit reduction >25%) in G6PD heterozygotes taking the higher (7 d) primaquine dose (9/17 [53%]) compared with G6PD heterozygotes taking the standard high (14 d) dose (2/16 [13%]; p = 0.022). In heterozygotes, the mean fractional haematocrit reductions were correspondingly greater with the higher primaquine dose (7-d regimen): -20.4% (95% CI -26.0% to -14.8%) (nadir on day 5) compared with the standard high (14 d) dose: -13.1% (95% CI -17.6% to -8.6%) (nadir day 6). Two heterozygotes taking the higher (7 d) primaquine dose required blood transfusion. In wild-type participants, mean haematocrit reductions were clinically insignificant and similar with both doses: -5.8 (95% CI -7.2% to -4.4%) (nadir day 3) compared with -5.5% (95% CI -7.4% to -3.7%) (nadir day 4), respectively. Limitations to this nested cohort study are that the primary objective of the trial was designed to measure efficacy and not haemolysis in relation to G6PD genotype and that the heterozygote groups were small. CONCLUSION: Higher daily doses of primaquine have the potential to cause clinically significant haemolysis in G6PD heterozygous females who are reported as phenotypically normal with current point of care tests. TRIAL REGISTRATION: ClinicalTrials.gov NCT01640574.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients having G6PD activities between 30–80% are under-studied, but there have been reports of a drop in hematocrit up to 30% requiring transfusion therapy following high dose of primaquine, some of those experiencing hemolytic crises as severe as homozygous females [23,24].”
In the citing paper
“Heterozygotes with intermediate enzyme activities (30%-70%) may screen as normal with qualitative tests and be given 8-aminoquinoline therapy with the attendant risk of AH; two G6PD Mahidol heterozygotes were transfused following exposure to 1 mg/kg of daily PQ[11].”
From Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria (2021) · cites this paper as [11]
In the citing paper
“Wide use of 8-aminoquinolines in malarious areas is hindered by the associated hemolytic risk in glucose-6-phosphate dehydrogenase (G6PD) deficient patients [5–7] and by the lack of suitable field testing.”
From Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood (2018) · cites this paper as [5]
In the citing paper
“As a consequence, primaquine is currently either administered in many women with a relatively high risk of hemolysis (in countries where treatment is dependent on RDT testing) [5], or it is not given at all due to safety concerns [18] in a large proportion of the population.”
From Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood (2018) · cites this paper as [5]
In the citing paper
“While G6PD deficiency can be diagnosed by qualitative tests in both males and females, female patients with intermediate G6PD activity who are at risk of hemolysis [5] cannot be diagnosed reliably by current qualitative tests.”
From Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Characterization of G6PD Genotypes and Phenotypes on the Northwestern Thailand-Myanmar Border
Bancone, G., Chu, C. S., Somsakchaicharoen, R., Chowwiwat, N., Parker, D. M., Charunwatthana, P., White, N. J., & Nosten, F. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116063 · Cited by 99
Self-citation
Cited by
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
Wheeler, E., Leong, A., Liu, C.-T., Hivert, M.-F., Strawbridge, R. J., Podmore, C., Li, M., Yao, J., Sim, X., Hong, J., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002383 · Cited by 408
Ceyhan-Birsoy, O., Murry, J. B., Machini, K., Lebo, M. S., Yu, T. W., Fayer, S., Genetti, C. A., Schwartz, T. S., Agrawal, P. B., Parad, R. B., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.11.016 · Cited by 306
Favism and Glucose-6-Phosphate Dehydrogenase Deficiency
Luzzatto, L., & Arese, P. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1708111 · Cited by 267
Watson, J., Taylor, W. R. J., Bancone, G., Chu, C. S., Jittamala, P., & White, N. J. (2018) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006440 · Cited by 77
Self-citation
Metadata
- Authors
- Chu, C. S., Bancone, G., Moore, K. A., Win, H. H., Thitipanawan, N., Po, C., Chowwiwat, N., Raksapraidee, R., Wilairisak, P., Phyo, A. P., Keereecharoen, L., Proux, S., Charunwatthana, P., Nosten, F., & White, N. J.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-02-07
- Volume
- 14
- Issue
- 2
- Pages
- e1002224
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2586377766
- Cited by
- 146
- References
- 1
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.